Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
The incoming Biden Administration is following tradition by announcing a regulatory freeze on Inauguration Day to pause action on recent Trump Administration regulations in order to consider withdrawing or revising them.
White House Chief of Staff Ron Klain sent a regulatory freeze memo to the heads of executive departments and agencies...
Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.
The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.
With the 4 July UK general election less than two weeks away, the Pink Sheet looks at the manifestos published by the major political parties and finds pledges to drive innovation, boost clinical trial activity and speed up regulatory procedures.
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.
Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.
Letter to US FDA by a bipartisan group of House members cites clinical trials sponsored by Eli Lilly and Pfizer as examples of a widespread industry practice. But any legislation to curtail such practices is not expected to be part of the BIOSECURE Act.
The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.
